Author

Kazumi Mori‐Anai

Observed name: Kazumi Mori-Anai

Institution: Tanabe Pharma Corporation (Japan)

Observed institution: Tanabe Pharma Corporation (Japan)

ORCID: 0000-0002-7353-4201

Observed ORCID: 0000-0002-7353-4201

OpenAlex ID: A5083876246

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study in Japan

2022 · Takashi Wada, Kazumi Mori‐Anai, et al. · Journal of Diabetes Investigation · 35

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial

2021 · Takashi Wada, Kazumi Mori‐Anai, et al. · Journal of Diabetes Investigation · 31

Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance

2021 · Nobuya Inagaki, Masaomi Nangaku, et al. · Advances in Therapy · 15

Mechanistic evaluation of the effect of sodium‐dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics

2020 · Kazumi Mori‐Anai, Yoshihiko Tashima, et al. · Biopharmaceutics & Drug Disposition · 8

Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases

2024 · Hiroaki Iijima, Maki Gouda, et al. · Diabetes Obesity and Metabolism · 5

Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model

2023 · Hiroaki Iijima, Hidetoshi Shimizu, et al. · Diabetes Therapy · 2

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan

2022 · Takashi Kadowaki, Nobuya Inagaki, et al. · Advances in Therapy · 1

Publisher Correction: Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model

2024 · Hiroaki Iijima, Hidetoshi Shimizu, et al. · Diabetes Therapy

Works count: 8

Citation count: 97

H-index: 5

I10-index: 3